SCHEMBL27192566

SCHEMBL27192566

COC(=O)c1ccc(C(C)Br)s1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.50
LMNA P02545 2/20 0.50
PPARG P37231 2/20 0.50
NCOA1 Q15788 2/20 0.50
NCOA3 Q9Y6Q9 2/20 0.50
NCOA2 Q15596 1/20 0.50
HPGD P15428 5/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
TSHR P16473 2/20 0.45
MAPK1 P28482 2/20 0.45
ATM Q13315 1/20 0.45
DAO P14920 1/20 0.42
KDM4E B2RXH2 3/20 0.40
MAPT P10636 1/20 0.40
ADRA2C P18825 1/20 0.38
MAOA P21397 1/20 0.38
ADRA1A P35348 1/20 0.38
DRD3 P35462 1/20 0.38
KCNH2 Q12809 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7454968 0.87 NPSR1 (0.51) NPSR1LMNAPPARGNCOA1NCOA3
SCHEMBL2403566 0.85 NPSR1 (0.53) NPSR1LMNAPPARGNCOA1NCOA3
SCHEMBL6983137 0.85 NPSR1 (0.46) NPSR1LMNAPPARGNCOA1NCOA3
SCHEMBL28012015 0.84 CA12 (0.41) NPSR1LMNAPPARGNCOA1NCOA3
SCHEMBL2654349 0.84 NPSR1 (0.51) NPSR1LMNAPPARGNCOA1NCOA3
SCHEMBL3333257 0.84 NPSR1 (0.51) NPSR1LMNAPPARGNCOA1NCOA3
SCHEMBL8254639 0.82 NPSR1 (0.50) NPSR1LMNAPPARGNCOA1NCOA3
SCHEMBL14448557 0.82 NPSR1 (0.50) NPSR1LMNAPPARGNCOA1NCOA3
SCHEMBL2406988 0.82 NPSR1 (0.50) NPSR1LMNAPPARGNCOA1NCOA3
Hydrochloric Acid SCHEMBL2408434 0.81 NPSR1 (0.49) NPSR1LMNAPPARGNCOA1NCOA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116910-A1 Heterocycles as WIP1 Inhibitors PMV PHARMACEUTICALS, INC. 2024-04-11 US disclosed
CN-103687856-B A novel 1,2,3,4-tetrahydroquinoline derivative useful for the treatment of diabetes LILLY CO ELI 2015-07-22 CN disclosed
CN-102648195-B Novel spiropiperidine compounds LILLY CO ELI 2015-01-07 CN disclosed
CN-102648195-A Novel spiropiperidine compounds LILLY CO ELI 2012-08-22 CN disclosed
CN-102131781-A 1-(4-ureidobenzoyl)piperazine derivatives ORGANON NV 2011-07-20 CN disclosed
CN-1759095-A N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARM INC (US) 2006-04-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116910-A1 Heterocycles as WIP1 Inhibitors WAPL, WHR1, G3BP1 NPSR1 4485/4885LMNA 4720/4885PPARG 2772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.